Tohoku University · Medicine
Professor Satoshi Yasuda's research lab specializes in clinical cardiovascular medicine, with a focus on optimizing antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. The lab conducts large-scale, evidence-based clinical trials to evaluate the efficacy and safety of novel anticoagulants, such as rivaroxaban, in real-world settings. Utilizing nationwide administrative databases like JROAD-DPC, the lab also investigates heart failure management and healthcare quality in Japan’s aging population. Their work bridges clinical practice and health policy to improve patient outcomes and guide evidence-based treatment strategies.
Figures are computed from collected data and may differ slightly.
As antithrombotic therapy, rivaroxaban monotherapy was noninferior to combination therapy for efficacy and superior for safety in patients with atrial fibrillation and stable coronary artery disease. (Funded by the Japan Cardiovascular Research Foundation; AFIRE UMIN Clinical Trials Registry number, UMIN000016612; and ClinicalTrials.gov number, NCT02642419.).
A nationwide administrative database of patients with cardiovascular diseases (JROAD-DPC) provided useful information that will contribute to improved quality of medical care, especially in the aging society of Japan, where HF has become an important health problem. (Circ J 2016; 80: 2327-2335).
Open papers in the app to read, cite, and organize with AI.
